Covid-19 Resource Center
Select region
Submit

Advanta V12 Balloon Expandable Covered Stent

Trusted. Reliable. Proven.

Trusted. Reliable. Proven.
Advanta V12 balloon expandable covered stent

For more than 15 years, by touching over 500,000 lives, our Advanta V12 balloon expandable covered stent has been trusted by physicians for its ease of use and proven, reliable outcomes.

Designed with a unique PTFE covering technology, Advanta V12 inspires confidence with high patency and low reintervention rates.[1] Backed by robust, long-term clinical data and over 500 publications, the Advanta V12 stent continues to prove itself every day.

Indications:

The Advanta V12 Covered Stent is indicated for restoring and improving the patency of the iliac and renal arteries. Renal approval includes 5mm, 6mm and 7mm diameter Advanta V12 sizes. In Canada, the Advanta V12 Covered stent indication excludes renal arteries.

 

The Advanta V12 Stent is not available in the U.S.

Conformable, deliverable, flexible

Designed to track through tortuous arteries and flex to accommodate the iliac and renal anatomy

Low profile

6Fr & 7Fr compatibility offers versatility and efficient delivery in complex endovascular procedures
9Fr compatibility for large diameter stents offers more options for percutaneous interventions

Ability to post-dilate

Allows a customized solution to various anatomy*

*Post dilation should always be performed following the guidelines within the Advanta V12 covered stent IFU

Trusted Design

Trusted Design
Journal of Vascular Surgery

Long-term positive outcomes of Getinge Advanta V12 stand out in new systematic literature review

The reliable outcomes of Getinge’s Advanta V12 has been confirmed again by a new systematic literature review. A group of physicians from around the world joined to compare published studies of covered balloon expandable (CBE) stents for aorto-iliac occlusive disease (AIOD) – and the Advanta V12/iCast device stands out as the only solution with most real world, long term data.

iCarus 3years study results

iCARUS: Single-Arm IDE Study with 3-Year Follow-Up

Freedom from Target Lesion Revascularization (TLR)

  • Real-world patient population with multiple lesions and bilateral disease
  • Study showed sustained clinical benefit with freedom from target lesion revascularization (TLR) up to 3 years[2]

Expert Experience with Advanta V12

 

COBEST Trial (part 2 of 5) - Results of the Study

Dr. Mwipatayi discusses what he sees as the most important clinical results of the study and how this could change the strategy for occlusive iliac treatment.

 

COBEST Trial (part 3 of 5) - Long Term Results

Dr. Mwipatayi discusses the five year advantage of using Advanta V12 compared to bare metal stents.

 

COBEST Trial (part 4 of 5) - Benefits of Advanta V12

Dr. Mwipatayi discusses the patency of Advanta V12 versus bare metal stents.

 

COBEST Trial (part 5 of 5) - Design of the Stent

Dr. Mwipatayi discusses the design advantage of the Advanta V12 balloon expandable covered stent.

  1. 1. Mwipatayi BP, Sharma S, Daneshmand A, et al. Durability of the balloon-expandable covered versus bare-metal stents in the Covered versus Balloon Expandable Stent Trial (COBEST) for the treatment of aortoiliac occlusive disease. J Vasc Surg. 2016. Jul;64(1):83-94.

  2. 2. Laird JR, Loja M, Zeller T, et al. iCAST Balloon-Expandable Covered Stent for Iliac Artery Lesions: 3-Year Results from the iCARUS Multicenter Study. J Vasc Interv Radiol. 2019 Jun;30(6)